Catalyst Pharmaceutical Inc. (CPRX)
Health Care ยท Pharmaceutical Preparations
Catalyst Pharmaceutical Inc. (CPRX) was listed on Nasdaq from November 8, 2006. SentiSense covers Catalyst Pharmaceutical Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Richard J. Daly is its chief executive officer. The company reports 182 employees, and its corporate website is www.catalystpharma.com.
About Catalyst Pharmaceutical Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Latest reported results
Catalyst Pharmaceuticals reported revenue of $149.4 million for Q1 FY2026, up 5.6% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 382 institutions reported holding CPRX, with 107.8 million shares worth $3.4 billion in aggregate. The largest reported holders were BlackRock, Vanguard and State Street. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on CPRX
- CPRX sentiment: whether news and social coverage of Catalyst Pharmaceutical Inc. leans bullish or bearish, and the stories driving it.
- CPRX ownership: all 382 reporting institutions, plus insider and congressional trades.
- CPRX financials: revenue, net income, operating margin and free cash flow through Q1 FY2026.
Frequently asked questions
What does Catalyst Pharmaceutical Inc. do?
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases.
What sector is CPRX in?
SentiSense classifies Catalyst Pharmaceutical Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where did CPRX stock trade?
Catalyst Pharmaceutical Inc. (CPRX) was listed on Nasdaq from November 8, 2006.
Who is the CEO of Catalyst Pharmaceutical Inc.?
Richard J. Daly is the chief executive officer of Catalyst Pharmaceutical Inc..